| Patient | John F. Kennedy |
|---|---|
| Date of birth | 1995-05-29 |
| Identifiers | MRN HR-ML023-SYN; SSN (made up) 000-23-5408 |
| Document date | 2026-11-01 |
| Author | Harlan Prescott, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care about three months after primary adrenal insufficiency was diagnosed during an adrenal crisis abroad: replacement doses, electrolytes and renin, cause, autoimmune screening, sick-day rules and emergency kit, and chronic low back pain. Concerns: He wants to understand his adrenal condition and to never again be as ill as he was abroad; He wants enough energy to keep a full working week, and to decide himself who knows about the diagnosis; He wants his back pain to stop limiting him and to rely less on the brace. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrocortisone 10 mg oral tablet, two tablets (20 mg) on waking and one tablet (10 mg) at 2 pm, 30 mg a day (started in hospital) | Two tablets on waking and one tablet at 2 pm | Oral route | 2025-10-06 to 2026-01-26 | completed | S |
| Fludrocortisone 0.1 mg oral tablet, half a tablet (0.05 mg) by mouth once daily (started in hospital) | Half a tablet by mouth once daily | Oral route | 2025-10-06 to 2026-01-26 | completed | S |
| Hydrocortisone 10 mg oral tablet, one tablet by mouth on waking | One tablet by mouth on waking | Oral route | 2026-01-26 | active | S |
| Hydrocortisone 5 mg oral tablet, one tablet by mouth at noon and one at 4 pm | One tablet at noon and one tablet at 4 pm (two doses a day) | Oral route | 2026-01-26 | active | S |
| Fludrocortisone 0.1 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-01-26 | active | S |
| Hydrocortisone 100 mg injection kit (with diluent), 100 mg into the thigh muscle once for vomiting, collapse or signs of adrenal crisis, then call 911 | Once, as needed for adrenal crisis; carry at all times | Intramuscular route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to three times a day as needed for back pain | Two tablets up to three times a day as needed | Oral route | 2026-01-12 | active | S |
| Oseltamivir 75 mg oral capsule, one capsule by mouth twice daily for five days | One capsule twice daily for five days | Oral route | 2026-02-16 to 2026-02-20 | completed | S |
| Levothyroxine 50 mcg oral tablet, one tablet by mouth each morning on an empty stomach | One tablet each morning, 30 to 60 minutes before breakfast | Oral route | 2026-03-09 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip | 2026-01-26 to 2026-01-26 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-08-17 to 2026-08-17 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-01-12 | Influenza vaccine, inactivated, this season | completed | S |
| 2026-08-17 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-08-17 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-10-19 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-19 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1920 | Scarlet fever in early childhood, with a month in the hospital | D (CLM-0002) |
| 1934 | Colitis diagnosed at the Mayo Clinic, with bowel symptoms and weight loss in his teens | D (CLM-0003) |
| 1937 | Steroid treatment for colitis during his college years, including steroids placed under the skin | D (CLM-0004) |
| 1937 | Back injury in a college football game, with back pain since and a corset brace | D (CLM-0006) |
| August 1943 | Back worsened during wartime naval service, when the boat he commanded was sunk; malaria in the Pacific | D (CLM-0007, CLM-0008) |
| June 1944 | Lumbar spine operation at New England Baptist Hospital; pain returned about six weeks later | D (CLM-0009) |
| 1947 | Collapse in England with a diagnosis of Addison's disease; so ill on the voyage home that he received the last rites; treated in Boston with desoxycorticosterone pellets | D (CLM-0011, CLM-0012, CLM-0013) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He wants to understand his adrenal condition and to never again be as ill as he was abroad | active | S |
| He wants enough energy to keep a full working week, and to decide himself who knows about the diagnosis | active | S |
| He wants his back pain to stop limiting him and to rely less on the brace | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.6 on 2026-01-12; Sodium [Moles/volume] in Serum or Plasma 135 on 2026-02-16; Potassium [Moles/volume] in Serum or Plasma 4.6 on 2026-02-16; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 2026-02-16; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 on 2026-02-16; Fasting glucose [Mass/volume] in Serum or Plasma 84 on 2026-01-12; Renin [Enzymatic activity/volume] in Plasma 2.2 on 2026-10-19; 21-Hydroxylase Ab [Units/volume] in Serum 18 on 2026-01-12; Thyrotropin [Units/volume] in Serum or Plasma 2 on 2026-10-19; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 on 2026-04-20; Thyroperoxidase Ab [Units/volume] in Serum or Plasma 286 on 2026-01-12; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 455 on 2026-01-12; Hemoglobin A1c/Hemoglobin.total in Blood 5.1 on 2026-01-12; Tissue transglutaminase IgA Ab [Units/volume] in Serum 1.1 on 2026-01-12; IgA [Mass/volume] in Serum or Plasma 214 on 2026-01-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 31 on 2026-01-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-10-19; Oswestry disability index score ODI 14 on 2026-10-19; DXA Lumbar spine [Z-score] Bone density -1.3 on 2026-01-26; DXA Femur [Z-score] Bone density -0.6 on 2026-01-26; Glucose [Mass/volume] in Serum or Plasma 96 on 2026-02-16; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-08-17; Total score [AUDIT-C] 2 on 2026-08-17 [S]
Strengths and supports: Supports: close friends he trusts, colleagues who cover for him on bad days, and work he finds meaningful; swimming eases his back [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Primary adrenal insufficiency (Addison's disease), diagnosed about three months ago during an adrenal crisis while traveling abroad, on hydrocortisone and fludrocortisone; synthetic modern episode linked to his documented 1947 diagnosis | active | confirmed | E27.1 | S — Synthetic modern coding of the documented diagnosis. |
| Chronic low back pain persisting after lumbar disc surgery; began after a football injury in college and worsened during wartime naval service; uses a corset brace; synthetic modern episode linked to his documented back history | active | confirmed | M96.1 | S — Synthetic modern coding of the documented back pain and operation. |
| Raised TSH with positive thyroid peroxidase antibodies and normal free T4 on screening for associated autoimmune disease; to be repeated before any treatment | resolved | confirmed | R94.6 | S — Synthetic screening finding. |
| Autoimmune (Hashimoto's) hypothyroidism, part of an autoimmune polyglandular syndrome with the adrenal insufficiency; started on levothyroxine | active | confirmed | E06.3 | S — Synthetic modern diagnosis anchored to his documented later hypothyroidism and its retrospective interpretation. |
| Influenza A with fever, managed at home with oseltamivir and doubled hydrocortisone under the sick-day rules; resolved | resolved | confirmed | J10.1 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-12 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-01-12 | Sodium [Moles/volume] in Serum or Plasma | 134 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-01-12 | Potassium [Moles/volume] in Serum or Plasma | 5.2 | mmol/L | 3.5-5.1 mmol/L | High | S |
| 2026-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 109 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-12 | Fasting glucose [Mass/volume] in Serum or Plasma | 84 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-12 | Renin [Enzymatic activity/volume] in Plasma | 9.6 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | High | S |
| 2026-01-12 | 21-Hydroxylase Ab [Units/volume] in Serum | 18 | U/mL | Below 1 U/mL: negative | High | S |
| 2026-01-12 | Thyrotropin [Units/volume] in Serum or Plasma | 7.4 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-01-12 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-01-12 | Thyroperoxidase Ab [Units/volume] in Serum or Plasma | 286 | [IU]/mL | <=34 [IU]/mL | High | S |
| 2026-01-12 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 455 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.1 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-01-12 | Tissue transglutaminase IgA Ab [Units/volume] in Serum | 1.1 | U/mL | Below 4 U/mL: negative | Normal | S |
| 2026-01-12 | IgA [Mass/volume] in Serum or Plasma | 214 | mg/dL | 70-400 mg/dL | Normal | S |
| 2026-01-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-01-12 | Oswestry disability index score ODI | 32 | {score} | S | ||
| 2026-01-26 | DXA Lumbar spine [Z-score] Bone density | -1.3 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-01-26 | DXA Femur [Z-score] Bone density | -0.6 | {Z-score} | Above -2.0 is within the expected range for age | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 112 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-09 | Renin [Enzymatic activity/volume] in Plasma | 2.6 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | Normal | S |
| 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 9.2 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-03-09 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.8 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-03-09 | Oswestry disability index score ODI | 26 | {score} | S | ||
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Thyrotropin [Units/volume] in Serum or Plasma | 3.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-04-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-04-20 | Oswestry disability index score ODI | 18 | {score} | S | ||
| 2026-10-19 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.95 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 110 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-19 | Renin [Enzymatic activity/volume] in Plasma | 2.2 | ng/mL/h | Upright, mid-morning: 0.6 to 4.3 ng/mL/h | Normal | S |
| 2026-10-19 | Thyrotropin [Units/volume] in Serum or Plasma | 2 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-10-19 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-10-19 | Oswestry disability index score ODI | 14 | {score} | S | ||
| 2026-02-16 | Sodium [Moles/volume] in Serum or Plasma | 135 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-16 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-16 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-16 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-139 mg/dL | Normal | S |
| 2026-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-08-17 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-12 | Body height | 183 | cm | S |
| 2026-01-12 | Body weight | 66 | kg | S |
| 2026-01-12 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-01-12 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-01-12 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-01-12 | Heart rate | 88 | /min | S |
| 2026-01-12 | Respiratory rate | 16 | /min | S |
| 2026-01-12 | Body temperature | 36.6 | Cel | S |
| 2026-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-01-26 | Body height | 183 | cm | S |
| 2026-01-26 | Body weight | 66.8 | kg | S |
| 2026-01-26 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 2026-01-26 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-01-26 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-01-26 | Heart rate | 84 | /min | S |
| 2026-01-26 | Respiratory rate | 14 | /min | S |
| 2026-01-26 | Body temperature | 36.7 | Cel | S |
| 2026-01-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-09 | Body height | 183 | cm | S |
| 2026-03-09 | Body weight | 69 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 76 | /min | S |
| 2026-03-09 | Respiratory rate | 14 | /min | S |
| 2026-03-09 | Body temperature | 36.6 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-20 | Body height | 183 | cm | S |
| 2026-04-20 | Body weight | 70.6 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 21.1 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 72 | /min | S |
| 2026-04-20 | Respiratory rate | 14 | /min | S |
| 2026-04-20 | Body temperature | 36.6 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-19 | Body height | 183 | cm | S |
| 2026-10-19 | Body weight | 72 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 21.5 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 70 | /min | S |
| 2026-10-19 | Respiratory rate | 14 | /min | S |
| 2026-10-19 | Body temperature | 36.6 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-16 | Body height | 183 | cm | S |
| 2026-02-16 | Body weight | 66.4 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 96 | /min | S |
| 2026-02-16 | Respiratory rate | 18 | /min | S |
| 2026-02-16 | Body temperature | 38.6 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-17 | Body height | 183 | cm | S |
| 2026-08-17 | Body weight | 71.4 | kg | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 21.3 | kg/m2 | S |
| 2026-08-17 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-08-17 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-17 | Heart rate | 70 | /min | S |
| 2026-08-17 | Respiratory rate | 14 | /min | S |
| 2026-08-17 | Body temperature | 36.6 | Cel | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-12 | Establishing primary care about three months after primary adrenal insufficiency was diagnosed during an adrenal crisis abroad: replacement doses, electrolytes and renin, cause, autoimmune screening, sick-day rules and emergency kit, and chronic low back pain | finished | S |
| 2026-01-26 | Two-week review and endocrinology consultation, with a bone density scan | finished | S |
| 2026-03-09 | Six-week review after the dose changes: electrolytes, renin, repeat thyroid tests, and back pain | finished | S |
| 2026-04-20 | Six-week review after starting levothyroxine | finished | S |
| 2026-10-19 | Nine-month review: replacement, thyroid, autoimmune screening, bone health, and back pain | finished | S |
| 2026-02-16 | Same-day sick visit for influenza with stress dosing of hydrocortisone | finished | S |
| 2026-08-17 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Glucocorticoid and mineralocorticoid replacement adjusted by clinical assessment at every visit (weight, blood pressure lying and standing, energy, salt craving, and signs of over- or under-replacement), with sodium, potassium and plasma renin to guide fludrocortisone; doses set with endocrinology | completed | GL-ES-PAI-2016 | S |
| Endocrinology consultation to confirm the cause, set the replacement doses, review the thyroid results and bone health, and plan stress dosing and follow-up | completed | GL-ES-PAI-2016 | S |
| Written sick-day rules (double the hydrocortisone for fever above 38 °C, triple it above 39 °C, and inject and seek emergency care if vomiting or unable to take tablets), an emergency hydrocortisone injection kit with training, a steroid emergency card and a medical ID, reviewed at every visit | completed | GL-ES-PAI-2016 | S |
| Screening for associated autoimmune disease: 21-hydroxylase antibodies for the cause, TSH, free T4 and thyroid peroxidase antibodies, vitamin B12, A1c and celiac serology with total IgA at intake; TSH at least yearly afterwards, and the others yearly or with symptoms | completed | GL-ES-PAI-2016, GL-CMID-2026, GL-ACG-CD-2023 | S |
| Chronic low back pain: physical therapy with core strengthening, swimming, heat, and gradual weaning from the brace except on long journeys; acetaminophen as needed; no opioids; Oswestry Disability Index at each review; imaging only for red flags | completed | GL-ACP-LBP-2017 | S |
| Bone health: a bone density scan because of corticosteroid exposure in his teens and twenties, calcium and vitamin D from diet, weight-bearing exercise, and avoiding glucocorticoid over-replacement | completed | GL-ACR-GIOP-2022, GL-ES-OPM-2012, GL-ES-PAI-2016 | S |
| Influenza: oseltamivir for five days, hydrocortisone doubled under the sick-day rules until a day without fever and then back to the usual dose, fluids with salt, and the emergency injection with a 911 call if he vomits or cannot take tablets | completed | GL-ES-PAI-2016, GL-CDC-FLU-AV | S |
| Autoimmune hypothyroidism: levothyroxine 50 mcg daily, started only after glucocorticoid replacement was secure; TSH 6 weeks after starting, again at 6 months, then yearly; target TSH 0.4 to 4.0 mIU/L | completed | GL-CMID-2026, GL-ATA-HYPO-2014, GL-ES-PAI-2016 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| No adrenal crisis and no emergency admission through nine months | 2026-10-19 | completed | No crisis or admission; one febrile illness managed at home with stress dosing | S |
| Hydrocortisone at the lowest dose that keeps him well, within 15 to 25 mg a day, with his weight back toward his usual 72 kg and no signs of over-replacement | 2026-10-19 | completed | Hydrocortisone 20 mg a day in three doses; weight 72.0 kg from 66.0; no signs of excess | S |
| Sodium and potassium normal, renin in the upper normal range, and no postural drop in blood pressure by the six-week review | 2026-03-09 | completed | Sodium 139, potassium 4.4 mmol/L; renin 2.6 ng/mL/h; no postural drop | S |
| He can state the sick-day rules and give the emergency injection by the two-week visit | 2026-01-26 | completed | Stated the rules and gave a practice injection on a trainer | S |
| Oswestry Disability Index below 20% by three months, with the brace used only for long travel | 2026-04-20 | completed | Oswestry 18% at three months; brace used only on long journeys | S |